



Statistical considerations AF-SCREEN Internationally


Shrikant I. Bangdiwala, PhD
Director, Statistics Department, PHRI



Research question & hypotheses

- ▶ Does screening for Atrial Fibrillation (AF) prevent ischemic strokes?
 - ▶ Screening for AF → detection of asymptomatic AF
 - ▶ Detection of asymptomatic AF → initiation of appropriate effective therapy (oral anticoagulants)
 - ▶ Initiation of appropriate effective therapy (oral anticoagulants)
 - increase risk-factor modifications to reduce complications from AF progression
 - reduce stroke and death

Study design flow diagram



▶ 3 0.010376 ← Risk of stroke in each arm → 0.010598

Study design flow diagram

- ▶ So the risk of stroke in each arm under these assumptions is

0.010376

0.010598



RR expected = 0.98
Meaningful?

- ▶ Consider translating outcome to # strokes prevented & quantity of \$\$ saved
- ▶ Varying paramters

Feasibility of a single-site RCT

- ▶ To test whether randomization to AF screening or not leads to fewer folks getting strokes
- ▶ For 80% power, need ~60,000 per arm


Numeric Results of Tests Based on the Difference: P1 - P2
 H0: P1 - P2 ≤ 0. H1: P1 - P2 = D1 > 0. Test Statistic: Z test with pooled variance

Target Power	Actual Power	N1	N2	N	Trt H1 P1	Cntrl P2	Diff D1	Target Alpha	Actual Alpha
0.80	0.80000			0	0.0104	0.0106	-0.0002	0.0500	

Effect Size

P1 (Treatment Group Proportion|H1):

P2 (Control Group Proportion):




Analytic methodology

- ▶ Calculate
 - ▶ Individual studies' intervention effect
 - ▶ Odds ratio, risk difference or risk ratio, mean difference, etc., standard error of estimate, 95% CI
 - ▶ Overall combined studies' intervention effect,
 - ▶ Standard error of estimate, 95% CI
 - ▶ Account for study-level characteristics, quality and differences
- ▶ Use random-effects meta analysis, enhanced with study-level characteristics & individual patient data → **multilevel meta-regression**

Additional slides


Meta analysis - methodology

Fixed-Effect Model



- ▶ Assumes all studies share a common effect-size μ
- ▶ Studies differ in their results due to sampling error ε
 - $G_i = \mu + \varepsilon_i$

Random-Effects Model



Underlying effects (θ) are normally distributed around some average effect (μ).

- ▶ Each study has its own effect-size that differs from μ by the 'study effect' ζ
- ▶ A study's result is also subject to sampling error ε
 - $G_i = \mu + \zeta_i + \varepsilon_i$

Meta analysis – estimation of overall effect

- ▶ The estimate is a weighted average, where the weight for a study is the reciprocal of its variance (as a measure of ‘quality’)
- ▶ The variance can be calculated using the fixed effects model or the random effects model:

- ▶ The fixed effects model does not use information from the other studies:

$$G_i = \mu + e_i$$

$$\text{var}(G_i) = \text{var}(e_i) = V_{G_i}$$

- ▶ The random effects model considers the variation among studies and within studies →

$$G_i = \mu + \zeta_i + e_i$$

$$\text{var}(\zeta) = \tau^2$$

$$\text{var}(G_i) = \tau^2 + V_{G_i}$$

Meta analysis – estimation of overall effect

- ▶ Weights with fixed effects

$$w_i = \frac{1}{V_{G_i}}$$

- ▶ Weights with random effects

$$w_i^* = \frac{1}{V_{G_i} + \hat{\tau}^2}$$

- ▶ Impact: ‘attenuation’ of weights if τ^2 is big

Random *versus* Fixed Effects

- ▶ If the study results are homogeneous, random and fixed effects will be almost identical
- ▶ If the study results are heterogeneous, the confidence interval for the random effects model will be wider than that for the fixed effects model

Assessing heterogeneity among studies


- ▶ **Cochran's Q** - the weighted sum of squared differences between individual study effects and the pooled effect across studies, with the weights being those used in the pooling method
 - ▶ $Q \sim \chi^2$ with $k-1$ df (k = number of studies)
- ▶ **I² statistic** - the percentage of variation across studies that is due to heterogeneity rather than chance
 - ▶ $I^2 = 100\% \times (Q-df)/Q$
 - ▶ Does not inherently depend upon the number of studies considered
- ▶ **τ^2** - variance component due to variation among studies

Meta analysis & meta regression

- ▶ **Dealing with ‘heterogeneity’ among the studies - τ^2**
 - ▶ Decompose the total variance into: among and within components → using mixed effects models for getting a more precise estimate of the intervention effect
- ▶ **If there is still residual heterogeneity**
 - ▶ Expand the mixed effects model to include study-level covariates that may explain some of the residual variability among studies → **meta regression**

Meta regression

► e.g.



Multi-level meta regression

- ▶ Incorporating individual-level variables into the meta-regression – for the j^{th} subject of the i^{th} study

